Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Investor Presentation (September 2023)
23 slides from Biovica International Ab Class B's investor presentation, Sep 14, 2023
Slide 1: Biovica: Treatment decisions with greater confidence
BI@VICA ‘TREATMENT DECISIONS WITH GREATER CONFIDENCE™
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: About the Presenter
About the Presenter Anders Rylander, CEO & Board Member . CEO & main shareholder in Biovica . Co-founder of Axholmen Management Consulting CTO at ICAAB . Senior Manager at Accenture
Slide 4: Company & Product; Market Potential & Plan; Summary & Milestones
® Company & Product - @Market Potential & Plan ® Summary & Milestones ©2023 Biovica International AB
Slide 5: An early indicator of effectiveness of cancer treatment
© Divitum® TKa An early indicator effectiveness of cancer treatment yr Progression at month | DiviTunt 9 T TKa 4 4 G @ > Month 0 | 2 3 4 + + —_| IMAGING | Progression at month 4 References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of can
Slide 6: Validated by a wealth of scientific evidence
@) Validated by a wealth of scientific evidence 30+ published and peer-reviewed articles Institutet Cancer Area Patients Nr. of studies ® Strong evidence supporting the use of Breast Cancer 3,039 44 DiviTum® TKa a linical biomarker ® sac b e Gastrointestinal 713 4 of CDK4/6i response Malignant Melan
Slide 7: Market Potential & Plan
Slide 8: Strategically designed launch plan ensures growth
(4) Strategically designed launch plan ensures growth © 18% 50% BREAST CANCER 7 chinared pohentd e of market otertial wee LAUNCH | — BUILD REVENUES 2S REALIZE POTENTIAL Bes " mUSDly OF |— LAUNCH — BUILD REVENUES -e— REALIZE POTENTIAL ne 150-300 |— oO REALIZE POTENTIAL e- LOCALLY ADVANCED ® es | Bene
Slide 9: We Continue to Execute the US Commercial Strategy
a We Continue to Execute the US Commercial Strategy — © Engagement and Feedback from KOL’s DiviTuns® Execute Client Bill (Hospital) Contracting TKa Expand Commercial Agreement Establish Coding, Pricing & Reimbursement @ Expanding Clinical Utility in Breast Cancer
Slide 10: Engagement & Feedback Drives Demand
£ (4) Engagement & Feedback Drives Demand = Focused Engagement with Targeted Medical Oncologists, KOLs and cancer centers drives SUCCESS Current Collaborators and Advisors (US) Engagement with all NCI Conducted clinical & NCCN designated presentations with 1500 cancer centers target Oncologists Feed
Slide 11: Execute Client Bill (hospital) Contracts
| . @ Execute Client Bill (hospital) Contracts (+ ) ~~ Client Bill Contracts drive accelerated growth Focus ® Expands access to all oncologists ; — NCI Designated Institutions @ Establishes ordering process at institutions : NCCN Designated Institutions ® Guarantees payment to Biovica — Notable Canc
Slide 12: Expand Commercial Agreements
£& C) Expand Commercial Agreements ad 3' commercial agreement with Occum (— ofe, \ @ e Health (July 2023) ¢ MediNcrease Health Plans™ vY Provide solutions to self insured employers for services performed by out of network providers contigohealth G) v_ Establish pre-negotiated rates for covered servi
Slide 13: Establish Coding, Pricing & Reimbursement
© Establish Coding, Pricing & Reimbursement = Coding and Pricing: Y Medicare credentialling (Mar 2023) EnsblespaymenytiomiMedicare PLA code is specific to DiviTtum TKa being run v AMAPLA code approved (Jul 2023) in our San Diego CLIA lab * CMS preliminary recommendation (Sep/Oct) Crosswalk or Gap fi
Slide 14: Expanding Clinical Utility in Breast Cancer
£ (3) Expanding Clinical Utility in Breast Cancer = Interventional Trials Observational Trials Yale Trial WashU — Impact Trial Real time biomarker of tumor response to CDK4/6 inhibition in HR+ metastatic breast cancer New Trials in Discussion New Trials in Discussion v Pls are KOLs & Thought v Gener
Slide 15: European Commercial Partner Strategy
~ European Commercial Partner Strategy ® —. partners with a proven track record launch and sales growth a | > — aS Europe milestones f ® 2023: First agreement, ~ KOL Support Account Contract additional to come @® 2023-25: Agreement(s) Oncologists in rest EU-5 + Nordics iii @® 2026: 15% of market —_—
Slide 16: Estimated TAM for EU-5 & Nordics is 150-250 mUSD/yr
() Estimated TAM for EU-5 & Nordics is 150-250 mUSD/yr @ ag ® ~15% of Europe TAM* ® Similar to Nordic markets @® Under serviced market ® Private Pay up to 40% ® Little Private Pay @ Private Pay up to 50% ® Strong KOL Support ® Strong KOL support @ CT-Scan very expensive 2023-25 Focus: Spain, Germany
Slide 17: The Pharma Services & Collaboration strategy
@ The Pharma Services & Collaboration strategy Q continues its strong progress with new agreements signed Q1 FY23/24 1. TESA 2. MSA 3. CDx Collaboration 4. CDx Product Technical Evaluation Master Service CDx Development CDx product on the market Service Agreement Agreement Collaboration (Revenues de
Slide 18: Summary & Milestones
® Summary & Milestones Biovica International AB
Slide 19: Summary & Milestones
Summary & Milestones Measures cell proliferation from a simple blood sample DiviTum® TKa addresses an important clinical unmet need DiviTum® TKa is supported by cancer KOL’s and scientific collaborators globally Market potential > $2 billion for monitoring of metastatic cancer (key indications on ke
Slide 20: Slide 20
Slide 21: Backup slides: The team
Backup slides The team
Slide 22: Board of Directors — many years of industry experience
Board of Directors — many years of industry experience! Lars Holmqvist Chairman Holdings: 659,436 B-shares, 100,000 warrants Maria Holmlund Board Member Holdings: 15,600 B-shares, 75,000 warrants Jesper Sdéderqvist Board Member Holdings: 41,085 A-shares, 61,120 B-shares, 75,000 warrants Marie Louise
Slide 23: Leadership Team — vast experience launching IVD
Leadership Team — vast experience launching IVD! Anders Rylander CEO Holdings: 3,575,640 A-shares, 1,562,074 B-shares, 90,000 warrants Hanna Ritzén coo. Holdings: 1,500 B-shares Warren Cresswell President Americas Holdings: 100.000 warrants Helle Fisker VP Commercial Europe Holdings: 18,700 B-shares
Biovica International — Investor Presentation (September 2023) on 6ix